These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Sep 5, 2013In Line with Independent Data Monitoring Committee’s (IDMC) Unanimous Recommendation, GSK will Continue Study Until Second Co-primary Endpoint is Assessed
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline’s (NYSE: GSK) DERMAi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3 cancer immunotherapeuticii (CI) trial, which...
Sep 4, 2013
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will present a corporate overview at two upcoming conferences....
Jul 25, 2013Agenus to Host Conference Call Beginning at 11 a.m. ET Today
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq:AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its...
Jul 22, 2013
Agenus Inc. (Nasdaq: AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the JMP Securities 8th Annual Healthcare...
Jul 18, 2013
Agenus Inc. (NASDAQ: AGEN) will release its second quarter 2013 financial results before the market opens on July 25, 2013. Agenus executives will host a conference call at 11:00 a.m. Eastern Time...